Barylski Marcin, Nikolic Dragana, Banach Maciej, Toth Peter P, Montalto Giuseppe, Rizzo Manfredi
Department of Internal Medicine and Medical Specialties, University of Palermo, Via del Vespro, 141, 90127, Palermo, Italy.
Curr Pharm Des. 2014;20(22):3657-64. doi: 10.2174/13816128113196660678.
Statins are highly efficacious lipid modifying agents that reduce the risk for cardiovascular (CV) events in both primary and secondary prevention settings. However, statins affect molecular mechanisms which adversely impact on insulin sensitivity and β-cell function, thereby increasing risk for new onset diabetes mellitus (NOD). Defining the mechanisms involved is the focus of considerable current investigation. The statins reduce the risk for CV events in normoglycemic patients as well as in those with diabetes mellitus (DM) and their benefits outweigh the risk of inducing NOD. We review the clinical evidence for NOD with statin treatment, as well as the potential mechanisms involved. Our literature search was based on PubMed and Scopus listings. Further large studies are needed to elucidate both the association between NOD and statin use and the underlying mechanisms.
他汀类药物是高效的脂质调节药物，在一级和二级预防中均可降低心血管（CV）事件风险。然而，他汀类药物会影响分子机制，对胰岛素敏感性和β细胞功能产生不利影响，从而增加新发糖尿病（NOD）风险。确定其中涉及的机制是当前大量研究的重点。他汀类药物可降低血糖正常患者以及糖尿病（DM）患者的CV事件风险，其益处超过诱发NOD的风险。我们综述了他汀类药物治疗导致NOD的临床证据以及潜在的相关机制。我们的文献检索基于PubMed和Scopus数据库列表。需要进一步开展大型研究，以阐明NOD与他汀类药物使用之间的关联及其潜在机制。
